Biomarker & Intervention Discovery

Peripheral Neuropathy (Diabetic Peripheral Neuropathy)

This page lists 10 druggable gene targets, 43 approved or trial-tested drug candidates and 15 recent clinical trials for Peripheral Neuropathy (Diabetic Peripheral Neuropathy), with each agent ranked by the strength of its evidence (clinical, mechanistic or correlative). Candidates include existing drugs that could be repurposed. Sources are linked so you can check every claim.

NIH funding$194MFY2025 · RCDC estimate
Spontaneous remissionProgressive with worsening glycaemic control; reversal essentially not possible with current treatments once…
Best-intervention remissionIntensive glycaemic control in T1DM (DCCT): 60% reduction in neuropathy development; pain management (duloxetine…
Gap sizeVery large — no disease-modifying therapy approved; pain treatment is the only intervention most patients receive
Primary barrierbiological (pain modification) + practice (prevention gap)
Full remission profile →
Research Tracker Chronic Disease Interventions Peripheral Neuropathy (Diabetic Peripheral Neuropathy)

Remission & chronicity

Spontaneous remission
Progressive with worsening glycaemic control; reversal essentially not possible with current treatments once established; spontaneous improvement only in cases of rapid glycaemic normalisation early in course
Best-intervention remission
Intensive glycaemic control in T1DM (DCCT): 60% reduction in neuropathy development; pain management (duloxetine, pregabalin): 30-50% pain reduction but no disease modification; alpha-lipoic acid IV: nerve conduction velocity improvement at 3 weeks (SYDNEY 2 trial); SGLT2 inhibitors: emerging data on neuropathy protection
Gap size
Very large — no disease-modifying therapy approved; pain treatment is the only intervention most patients receive
Primary barrier
biological (pain modification) + practice (prevention gap)
Prevention through glycaemic control is highly effective but prevention means tight glycaemic control for decades; pain treatment gives symptomatic relief only; opioid prescribing for DPN pain remains common despite guidelines against it; few patients are offered alpha-lipoic acid which has the strongest disease-modification signal

Biomarker Targets & Therapeutic Agents

Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: Clinical > Mechanistic > Correlative.

AKR1B1 201CACNA2D1 220NGF 9OPRM1 377SCN10A 289SCN9A 280SLC6A2 281SLC6A4 234TRPA1 186TRPV1 187

AKR1B1

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
SULINDAC ? unclear Mechanistic DGIdb
TECTORIGENIN ? unclear Mechanistic DGIdb
ANTISERUM ? unclear Mechanistic DGIdb
SORBINIL ↓ inhibits Mechanistic 120.0 nM (IC50) DGIdb
THERAPEUTIC GROWTH FACTOR ? unclear Mechanistic DGIdb
MANGIFERIN ↓ inhibits Mechanistic DGIdb
LIDORESTAT ? unclear Mechanistic DGIdb
EPALRESTAT ↓ inhibits Mechanistic DGIdb
CAFICRESTAT ↓ inhibits Mechanistic DGIdb
ZENARESTAT ↓ inhibits Mechanistic 42.4 nM (IC50) DGIdb
ZOPOLRESTAT ↓ inhibits Mechanistic 4.8 nM (IC50) DGIdb
QR-333 ? unclear Mechanistic DGIdb
LIDORESTAT ANHYDROUS ↓ inhibits Mechanistic DGIdb
GOVORESTAT ↓ inhibits Mechanistic DGIdb
AK198 ↓ inhibits Mechanistic DGIdb
RANIRESTAT ? unclear Mechanistic DGIdb
URACIL ? unclear Mechanistic DGIdb
TOLRESTAT ↓ inhibits Mechanistic 47.0 nM (IC50) DGIdb
FIDARESTAT ? unclear Mechanistic DGIdb
CHEMBL18854 ↓ inhibits Mechanistic 230.0 nM (IC50) ChEMBL
CHEMBL19744 ↓ inhibits Mechanistic 130.0 nM (IC50) ChEMBL
CHEMBL19711 ↓ inhibits Mechanistic 100.0 nM (IC50) ChEMBL
CHEMBL19392 ↓ inhibits Mechanistic 5630.0 nM (IC50) ChEMBL
CHEMBL19746 ↓ inhibits Mechanistic 7470.0 nM (IC50) ChEMBL
CHEMBL19781 ↓ inhibits Mechanistic 470.0 nM (IC50) ChEMBL
CHEMBL19649 ↓ inhibits Mechanistic 270.0 nM (IC50) ChEMBL
CHEMBL440790 ↓ inhibits Mechanistic 580.0 nM (IC50) ChEMBL
CHEMBL429059 ↓ inhibits Mechanistic 580.0 nM (IC50) ChEMBL
CHEMBL18865 ↓ inhibits Mechanistic 380.0 nM (IC50) ChEMBL
CHEMBL19316 ↓ inhibits Mechanistic 220.0 nM (IC50) ChEMBL
CHEMBL19789 ↓ inhibits Mechanistic 1200.0 nM (IC50) ChEMBL
CHEMBL2310845 ↓ inhibits Mechanistic 100000.0 nM (IC50) ChEMBL
CHEMBL19064 ↓ inhibits Mechanistic 700.0 nM (IC50) ChEMBL
CHEMBL19187 ↓ inhibits Mechanistic 30.0 nM (IC50) ChEMBL
CHEMBL277427 ↓ inhibits Mechanistic 610.0 nM (IC50) ChEMBL
CHEMBL278565 ↓ inhibits Mechanistic 3870.0 nM (IC50) ChEMBL
CHEMBL277520 ↓ inhibits Mechanistic 50.0 nM (IC50) ChEMBL
CHEMBL280357 ↓ inhibits Mechanistic 4470.0 nM (IC50) ChEMBL
CHEMBL19495 ↓ inhibits Mechanistic 180.0 nM (IC50) ChEMBL
CHEMBL443492 ↓ inhibits Mechanistic 250.0 nM (IC50) ChEMBL

Showing top 40 of 201 agents ranked by evidence tier.

CACNA2D1

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
IMAGABALIN ~ modulates Mechanistic DGIdb
PREGABALIN ~ modulates Mechanistic 19.0 nM (Ki) DGIdb
IBUTILIDE ? unclear Mechanistic DGIdb
GABAPENTIN ENACARBIL ~ modulates Mechanistic DGIdb
GABAPENTIN ~ modulates Mechanistic 27.0 nM (IC50) DGIdb
PHLOROGLUCINOL ↓ inhibits Mechanistic DGIdb
SULOCTIDIL ↓ inhibits Mechanistic DGIdb
MIROGABALIN ? unclear Mechanistic DGIdb
AMLODIPINE BESYLATE ? unclear Mechanistic DGIdb
TERODILINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
DILTIAZEM HYDROCHLORIDE ? unclear Mechanistic DGIdb
ATAGABALIN ~ modulates Mechanistic DGIdb
LERCANIDIPINE ? unclear Mechanistic DGIdb
NITRENDIPINE ? unclear Mechanistic DGIdb
MIROGABALIN BESYLATE ~ modulates Mechanistic DGIdb
NIFEDIPINE ? unclear Mechanistic DGIdb
ISRADIPINE ? unclear Mechanistic DGIdb
CELECOXIB ? unclear Mechanistic DGIdb
BEPRIDIL HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
FELODIPINE ? unclear Mechanistic DGIdb
SAFINAMIDE ? unclear Mechanistic DGIdb
BEPRIDIL ? unclear Mechanistic Open Targets
TERODILINE ? unclear Mechanistic Open Targets
CHEMBL79968 ↓ inhibits Mechanistic 145.0 nM (IC50) ChEMBL
CHEMBL84067 ↓ inhibits Mechanistic 72.0 nM (IC50) ChEMBL
CHEMBL418920 ↓ inhibits Mechanistic 241.0 nM (IC50) ChEMBL
CHEMBL84228 ↓ inhibits Mechanistic 15.0 nM (IC50) ChEMBL
CHEMBL79606 ↓ inhibits Mechanistic 198.0 nM (IC50) ChEMBL
CHEMBL81141 ↓ inhibits Mechanistic 220.0 nM (IC50) ChEMBL
CHEMBL79559 ↓ inhibits Mechanistic 260.0 nM (IC50) ChEMBL
CHEMBL81225 ↓ inhibits Mechanistic 145.0 nM (IC50) ChEMBL
CHEMBL81850 ↓ inhibits Mechanistic 131.0 nM (IC50) ChEMBL
CHEMBL420593 ↓ inhibits Mechanistic 630.0 nM (IC50) ChEMBL
CHEMBL310121 ↓ inhibits Mechanistic 28.0 nM (IC50) ChEMBL
CHEMBL79762 ↓ inhibits Mechanistic 161.0 nM (IC50) ChEMBL
CHEMBL79400 ↓ inhibits Mechanistic 194.0 nM (IC50) ChEMBL
CHEMBL81851 ↓ inhibits Mechanistic 342.0 nM (IC50) ChEMBL
CHEMBL430820 ↓ inhibits Mechanistic 29.0 nM (IC50) ChEMBL
CHEMBL1169381 ↓ inhibits Mechanistic 30.0 nM (IC50) ChEMBL
CHEMBL311519 ↓ inhibits Mechanistic 1369.0 nM (IC50) ChEMBL

Showing top 40 of 220 agents ranked by evidence tier.

NGF

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
FASINUMAB ? unclear Mechanistic DGIdb
CERE-110 ? unclear Mechanistic DGIdb
TANEZUMAB ? unclear Mechanistic DGIdb
FRUNEVETMAB ~ modulates Mechanistic DGIdb
FULRANUMAB ↓ inhibits Mechanistic DGIdb
PG-110 ↓ inhibits Mechanistic DGIdb
BEDINVETMAB ~ modulates Mechanistic DGIdb
MEDI-578 ↓ inhibits Mechanistic DGIdb
CHEMBL1397270 ↓ inhibits Mechanistic 1000.0 nM (IC50) ChEMBL

OPRM1

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
AXOMADOL ↑ activates Mechanistic DGIdb
BMS-986121 ~ modulates Mechanistic DGIdb
DEXTROAMPHETAMINE SULFATE ? unclear Mechanistic DGIdb
METHADONE HYDROCHLORIDE ↑ activates Mechanistic DGIdb
HYDROCODONE POLISTIREX ↑ activates Mechanistic DGIdb
CHEMBL:CHEMBL570176 ? unclear Mechanistic DGIdb
OXYCODONE HYDROCHLORIDE ↑ activates Mechanistic DGIdb
BEVENOPRAN ↓ inhibits Mechanistic DGIdb
EG-1-230 ↑ activates Mechanistic DGIdb
TAPENTADOL ↑ activates Mechanistic DGIdb
BUTORPHANOL ↑ activates Mechanistic DGIdb
CTOP ↓ inhibits Mechanistic DGIdb
NAVACAPRANT ↓ inhibits Mechanistic DGIdb
NALOXONE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
CODEINE POLISTIREX ↑ activates Mechanistic DGIdb
LOPERAMIDE ↑ activates Mechanistic DGIdb
ANILERIDINE ? unclear Mechanistic DGIdb
LOFENTANIL ↑ activates Mechanistic DGIdb
LEVOMETHADYL ACETATE HYDROCHLORIDE ↑ activates Mechanistic DGIdb
DEZOCINE ↑ activates Mechanistic DGIdb
FENTANYL HYDROCHLORIDE ↑ activates Mechanistic DGIdb
QUADAZOCINE ↓ inhibits Mechanistic DGIdb
OXYMORPHONE ? unclear Mechanistic DGIdb
NALDEMEDINE TOSYLATE ↓ inhibits Mechanistic DGIdb
ALFENTANIL HYDROCHLORIDE ↑ activates Mechanistic DGIdb
ANTICONVULSANT AGENT ? unclear Mechanistic DGIdb
FENTANYL CITRATE ↑ activates Mechanistic DGIdb
NALTREXONE ↓ inhibits Mechanistic DGIdb
NALMEFENE ↓ inhibits Mechanistic DGIdb
REMIFENTANIL HYDROCHLORIDE ? unclear Mechanistic DGIdb
OXYCODONE ↑ activates Mechanistic DGIdb
NALTRIBEN ↓ inhibits Mechanistic DGIdb
PAREGORIC ↑ activates Mechanistic DGIdb
OXYMORPHONE HYDROCHLORIDE ↑ activates Mechanistic DGIdb
ATOXIFENT ↑ activates Mechanistic DGIdb
DYNORPHIN A ↑ activates Mechanistic DGIdb
ERGOT ALKALOIDS ? unclear Mechanistic DGIdb
ALVIMOPAN ANHYDROUS ↓ inhibits Mechanistic DGIdb
METHYLSAMIDORPHAN ↓ inhibits Mechanistic DGIdb
DYNORPHIN A-(1-13) ↑ activates Mechanistic DGIdb

Showing top 40 of 377 agents ranked by evidence tier.

SCN10A

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
DYCLONINE ? unclear Mechanistic DGIdb
ZONISAMIDE ↓ inhibits Mechanistic DGIdb
FUNAPIDE ↓ inhibits Mechanistic 4800.0 nM (IC50) DGIdb
HEXYLCAINE ? unclear Mechanistic DGIdb
PROCAINE ? unclear Mechanistic DGIdb
DRONEDARONE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
NKTR-171 ↓ inhibits Mechanistic DGIdb
LAMOTRIGINE ↓ inhibits Mechanistic 96000.0 nM (IC50) DGIdb
ESLICARBAZEPINE ↓ inhibits Mechanistic DGIdb
BUPIVACAINE ? unclear Mechanistic DGIdb
DIBUCAINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
MEXILETINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
ANP-230 ↓ inhibits Mechanistic DGIdb
AFACIFENACIN ↓ inhibits Mechanistic DGIdb
BENOXINATE ? unclear Mechanistic DGIdb
LTGO-33 ↓ inhibits Mechanistic DGIdb
A-887826 ↓ inhibits Mechanistic DGIdb
DISOPYRAMIDE PHOSPHATE ↓ inhibits Mechanistic DGIdb
ORPHENADRINE CITRATE ↓ inhibits Mechanistic DGIdb
ETIDOCAINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
EVENAMIDE ↓ inhibits Mechanistic DGIdb
DSP-2230 ↓ inhibits Mechanistic DGIdb
DYCLONINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
CHLOROPROCAINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
CHLOROPROCAINE ? unclear Mechanistic DGIdb
COCAINE ? unclear Mechanistic DGIdb
OXCARBAZEPINE ↓ inhibits Mechanistic DGIdb
PROPAFENONE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
BENZOCAINE ? unclear Mechanistic DGIdb
PHENAZOPYRIDINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
ORPHENADRINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
PROPARACAINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
PHENYTOIN SODIUM ↓ inhibits Mechanistic DGIdb
QUINIDINE POLYGALACTURONATE ↓ inhibits Mechanistic DGIdb
PROPOXYCAINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
PF-04531083 ↓ inhibits Mechanistic 700.0 nM (IC50) DGIdb
DICHLOROBENZYL ALCOHOL ↓ inhibits Mechanistic DGIdb
VX-150 ↓ inhibits Mechanistic DGIdb
PROCAINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
ROPIVACAINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb

Showing top 40 of 289 agents ranked by evidence tier.

SCN9A

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
TETRODOTOXIN ↓ inhibits Mechanistic DGIdb
XEN403 ↓ inhibits Mechanistic DGIdb
IRAMPANEL ↓ inhibits Mechanistic DGIdb
XEN907 ↓ inhibits Mechanistic DGIdb
N-ME-AMINOPYRIMIDINONE 9 ↓ inhibits Mechanistic DGIdb
PF‐06526290 ↓ inhibits Mechanistic DGIdb
QUINIDINE POLYGALACTURONATE ↓ inhibits Mechanistic DGIdb
VIXOTRIGINE ↓ inhibits Mechanistic DGIdb
LIDOCAINE ↓ inhibits Mechanistic DGIdb
FUNAPIDE ↓ inhibits Mechanistic DGIdb
CD2+ ↓ inhibits Mechanistic DGIdb
PHENYTOIN SODIUM ↓ inhibits Mechanistic DGIdb
HEXYLCAINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
ESLICARBAZEPINE ACETATE ↓ inhibits Mechanistic DGIdb
DICHLOROBENZYL ALCOHOL ↓ inhibits Mechanistic DGIdb
PROPOFOL ? unclear Mechanistic DGIdb
OXCARBAZEPINE ↓ inhibits Mechanistic DGIdb
ORPHENADRINE CITRATE ↓ inhibits Mechanistic DGIdb
NERISPIRDINE ↓ inhibits Mechanistic DGIdb
CHLOROPROCAINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
MEPHENYTOIN ↓ inhibits Mechanistic DGIdb
ANP-230 ↓ inhibits Mechanistic DGIdb
ABBV-318 ↓ inhibits Mechanistic DGIdb
MEPIVACAINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
AMOROLFINE ↓ inhibits Mechanistic DGIdb
RUFINAMIDE ↓ inhibits Mechanistic DGIdb
EVENAMIDE ↓ inhibits Mechanistic DGIdb
SAFINAMIDE ? unclear Mechanistic DGIdb
NKTR-171 ↓ inhibits Mechanistic DGIdb
RG6029 ↓ inhibits Mechanistic DGIdb
RALFINAMIDE ↓ inhibits Mechanistic DGIdb
ZONISAMIDE ↓ inhibits Mechanistic DGIdb
BIIB-095 ? unclear Mechanistic DGIdb
RG7893 ↓ inhibits Mechanistic DGIdb
ARTICAINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
DISOPYRAMIDE PHOSPHATE ↓ inhibits Mechanistic DGIdb
PROPOXYCAINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
TOCAINIDE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
TETRACAINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
MERETHOXYLLINE PROCAINE ↓ inhibits Mechanistic DGIdb

Showing top 40 of 280 agents ranked by evidence tier.

SLC6A2

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
GUANETHIDINE ? unclear Mechanistic DGIdb
BUPROPION HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
TRIMIPRAMINE ↓ inhibits Mechanistic DGIdb
DIETHYLPROPION ? unclear Mechanistic DGIdb
LEVOMILNACIPRAN ↓ inhibits Mechanistic DGIdb
DOXEPIN HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
DULOXETINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
DASOTRALINE ↓ inhibits Mechanistic DGIdb
SERDEXMETHYLPHENIDATE ↓ inhibits Mechanistic DGIdb
ZOTEPINE ↓ inhibits Mechanistic DGIdb
LOFEPRAMINE ↓ inhibits Mechanistic DGIdb
LISDEXAMFETAMINE DIMESYLATE ? unclear Mechanistic DGIdb
NEFAZODONE ↓ inhibits Mechanistic 360.0 nM (Kd) DGIdb
3-IODOBENZYLGUANIDINE ? unclear Mechanistic DGIdb
PHENTERMINE RESIN ? unclear Mechanistic DGIdb
REBOXETINE ↓ inhibits Mechanistic 1.1 nM (Ki) DGIdb
NORZOTEPINE ↓ inhibits Mechanistic DGIdb
ATOMOXETINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
SERDEXMETHYLPHENIDATE CHLORIDE ↓ inhibits Mechanistic DGIdb
SOLRIAMFETOL ↓ inhibits Mechanistic DGIdb
DESIPRAMINE ↓ inhibits Mechanistic DGIdb
METHYLPHENIDATE ↓ inhibits Mechanistic DGIdb
AMPRELOXETINE ↓ inhibits Mechanistic DGIdb
MILNACIPRAN ↓ inhibits Mechanistic DGIdb
ORPHENADRINE CITRATE ↓ inhibits Mechanistic DGIdb
AMITRIPTYLINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
[3H]NISOXETINE ↓ inhibits Mechanistic DGIdb
PHENDIMETRAZINE TARTRATE ↓ inhibits Mechanistic DGIdb
LEVOMILNACIPRAN HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
METHAMPHETAMINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
AMITIFADINE HYDROCHLORIDE ? unclear Mechanistic DGIdb
AMOXAPINE ↓ inhibits Mechanistic DGIdb
QUETIAPINE FUMARATE ↓ inhibits Mechanistic DGIdb
AMITIFADINE ? unclear Mechanistic DGIdb
VENLAFAXINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
HINOKININ ? unclear Mechanistic DGIdb
TESOFENSINE ? unclear Mechanistic DGIdb
TEDATIOXETINE ? unclear Mechanistic DGIdb
MAZINDOL ↓ inhibits Mechanistic 18.0 nM (Ki) DGIdb
AMPHETAMINE ASPARTATE ? unclear Mechanistic DGIdb

Showing top 40 of 281 agents ranked by evidence tier.

SLC6A4

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
CLOMIPRAMINE ↓ inhibits Mechanistic 70.0 nM (IC50) DGIdb
CITALOPRAM ↓ inhibits Mechanistic 1.6 nM (Ki) DGIdb
FLUVOXAMINE ↓ inhibits Mechanistic DGIdb
MILNACIPRAN ↓ inhibits Mechanistic DGIdb
PHENELZINE ↓ inhibits Mechanistic DGIdb
FLUOXETINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
3,4-METHYLENEDIOXYMETHAMPHETAMINE ? unclear Mechanistic DGIdb
BL-1021 ? unclear Mechanistic DGIdb
FLUVOXAMINE MALEATE ? unclear Mechanistic DGIdb
VENLAFAXINE ↓ inhibits Mechanistic 8.9 nM (Kd) DGIdb
DESVENLAFAXINE FUMARATE ↓ inhibits Mechanistic DGIdb
DESVENLAFAXINE SUCCINATE ↓ inhibits Mechanistic DGIdb
NORTRIPTYLINE ↓ inhibits Mechanistic DGIdb
ACETAMINOPHEN ? unclear Mechanistic DGIdb
FAXELADOL ↓ inhibits Mechanistic DGIdb
TEDATIOXETINE ? unclear Mechanistic DGIdb
MINAPRINE ? unclear Mechanistic DGIdb
TRAZODONE ? unclear Mechanistic DGIdb
SERTRALINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
LIAFENSINE ↓ inhibits Mechanistic DGIdb
DAPOXETINE ↓ inhibits Mechanistic DGIdb
MAZINDOL ↓ inhibits Mechanistic 50.0 nM (Ki) DGIdb
VORTIOXETINE HYDROBROMIDE ↓ inhibits Mechanistic DGIdb
COCAINE ? unclear Mechanistic 270.0 nM (IC50) DGIdb
DULOXETINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
PAROXETINE HYDROCHLORIDE, HEMIHYDRATE ↓ inhibits Mechanistic DGIdb
NORTRIPTYLINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
TRIMIPRAMINE ↓ inhibits Mechanistic DGIdb
LUMATEPERONE ↓ inhibits Mechanistic DGIdb
AMITIFADINE ↓ inhibits Mechanistic DGIdb
NEFAZODONE ↓ inhibits Mechanistic 200.0 nM (Kd) DGIdb
ATOMOXETINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
CHLORPHENTERMINE HYDROCHLORIDE ? unclear Mechanistic DGIdb
TRAZODONE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
DEXFENFLURAMINE ? unclear Mechanistic DGIdb
DOXEPIN HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
N-DESMETHYLCLOZAPINE ? unclear Mechanistic DGIdb
IBOGAINE ↓ inhibits Mechanistic DGIdb
LEVOMILNACIPRAN ↓ inhibits Mechanistic DGIdb
PSEUDOEPHEDRINE POLISTIREX ? unclear Mechanistic DGIdb

Showing top 40 of 234 agents ranked by evidence tier.

TRPA1

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
ASP7663 ↑ activates Mechanistic DGIdb
NPPB ↑ activates Mechanistic DGIdb
VOACANGINE ? unclear Mechanistic DGIdb
METHYLGLYOXAL ↑ activates Mechanistic DGIdb
ALLYL ISOTHIOCYANATE ↑ activates Mechanistic 33500.0 nM (EC50) DGIdb
BENZYL BROMIDE ↑ activates Mechanistic 12000.0 nM (EC50) DGIdb
1,6-HEXAMETHYLENE DIISOCYANATE ↑ activates Mechanistic DGIdb
BROMOACETONE ↑ activates Mechanistic DGIdb
ACETALDEHYDE ↑ activates Mechanistic DGIdb
ISOVELLERAL ↑ activates Mechanistic 590.0 nM (EC50) DGIdb
POLYGODIAL ↑ activates Mechanistic 59.0 nM (EC50) DGIdb
CISPLATIN ? unclear Mechanistic DGIdb
ISOPROPYL ISOTHIOCYANATE ? unclear Mechanistic DGIdb
A-967079 ↓ inhibits Mechanistic DGIdb
NITROOLEIC ACID ↑ activates Mechanistic DGIdb
PHENETHYLISOTHIOCYANATE ? unclear Mechanistic 10000.0 nM (EC50) DGIdb
PF-4840154 ↑ activates Mechanistic DGIdb
4-HYDROXYNONENAL ? unclear Mechanistic DGIdb
AM-0902 ↓ inhibits Mechanistic DGIdb
ACROLEIN ↑ activates Mechanistic 5000.0 nM (EC50) DGIdb
1'-ACETOXYCHAVICOL ACETATE ↑ activates Mechanistic DGIdb
GDC-0334 ↓ inhibits Mechanistic DGIdb
METHYL ISOCYANATE ↑ activates Mechanistic DGIdb
BUTAMBEN ↓ inhibits Mechanistic DGIdb
ERUCIN ? unclear Mechanistic DGIdb
CHLOROPICRIN ↑ activates Mechanistic DGIdb
SALIRASIB ↑ activates Mechanistic 5000.0 nM (EC50) DGIdb
BUTAMBEN PICRATE ↓ inhibits Mechanistic DGIdb
MENTHOL ↑ activates Mechanistic 28400.0 nM (EC50) DGIdb
CHLOROBENZYLIDENE MALONONITRILE ↑ activates Mechanistic DGIdb
HC030031 ↓ inhibits Mechanistic DGIdb
URB597 ↑ activates Mechanistic DGIdb
JT010 ↑ activates Mechanistic DGIdb
DIBUTYLPHTHALATE ↑ activates Mechanistic DGIdb
AP18 ↓ inhibits Mechanistic DGIdb
TCS 5861528 ↓ inhibits Mechanistic DGIdb
APOMORPHINE ↑ activates Mechanistic DGIdb
CB-189625 ↓ inhibits Mechanistic DGIdb
BENZOQUINONE ↑ activates Mechanistic DGIdb
GRC-17536 ↓ inhibits Mechanistic DGIdb

Showing top 40 of 186 agents ranked by evidence tier.

TRPV1

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
RHTX ↑ activates Mechanistic DGIdb
ABT-102 ↓ inhibits Mechanistic DGIdb
ASIVATREP ↓ inhibits Mechanistic DGIdb
BCTC ↓ inhibits Mechanistic DGIdb
MAVATREP ↓ inhibits Mechanistic DGIdb
POLYGODIAL ? unclear Mechanistic DGIdb
ALLICIN ↓ inhibits Mechanistic DGIdb
JTS-653 ↓ inhibits Mechanistic DGIdb
SB452533 ↓ inhibits Mechanistic DGIdb
MR-1817 ↓ inhibits Mechanistic DGIdb
GRC-6211 ↓ inhibits Mechanistic DGIdb
ACETAMINOPHEN ↑ activates Mechanistic DGIdb
DWP05195 ↓ inhibits Mechanistic DGIdb
STREPTOZOCIN ? unclear Mechanistic DGIdb
CAPSAICIN ↑ activates Mechanistic 19.95 nM (EC50) DGIdb
AMG517 ↓ inhibits Mechanistic DGIdb
5S-HETE ↑ activates Mechanistic DGIdb
BENZYL ISOTHIOCYANATE ? unclear Mechanistic DGIdb
MASOPROCOL ? unclear Mechanistic DGIdb
[3H]RESINIFERATOXIN ↑ activates Mechanistic DGIdb
[3H]A778317 ↓ inhibits Mechanistic DGIdb
CAPSAZEPINE ↓ inhibits Mechanistic 120.0 nM (Ki) DGIdb
NABIXIMOLS ? unclear Mechanistic DGIdb
H+ ↑ activates Mechanistic DGIdb
RECOMBINANT TUMOR NECROSIS FACTOR FAMILY PROTEIN ? unclear Mechanistic DGIdb
NADA ↓ inhibits Mechanistic DGIdb
ZUCAPSAICIN ↑ activates Mechanistic DGIdb
SB366791 ↓ inhibits Mechanistic DGIdb
GRC-15300 ? unclear Mechanistic DGIdb
MRS-1477 ~ modulates Mechanistic DGIdb
ANANDAMIDE ↑ activates Mechanistic DGIdb
JNJ17203212 ↓ inhibits Mechanistic DGIdb
LEVODOPA ? unclear Mechanistic DGIdb
INDOMETHACIN ? unclear Mechanistic DGIdb
AZD1386 ↓ inhibits Mechanistic DGIdb
CAMPHOR OIL ↑ activates Mechanistic DGIdb
ISOPROPYL ISOTHIOCYANATE ? unclear Mechanistic DGIdb
VOACANGINE ? unclear Mechanistic DGIdb
FERRUGINENE B ? unclear Mechanistic DGIdb
PHENYLACETYLRINVANIL ↑ activates Mechanistic DGIdb

Showing top 40 of 187 agents ranked by evidence tier.

Clinical Trials

Drug, biologic and supplement trials (treatment or prevention) from ClinicalTrials.gov whose main condition is Peripheral Neuropathy (Diabetic Peripheral Neuropathy): recruiting, active or completed, most recently updated first. Data retrieved 2026-10-28.

The Effects of Ceylon Cinnamon (Cinnamomum Verum) Supplementation on Blood Glucose, Lipid Profile Levels, Body Mass Index, and Pain Intensity Among Adult Individuals With Painful Diabetic Peripheral Neuropathy Recruiting
NCT07743073 Phase: N/A Started: 2026-02-01

Background: Painful diabetic peripheral neuropathy (PDPN) is a severe, disabling complication of type 2 diabetes mellitus (T2DM), closely associated with insulin resistance, chronic neuroinflammation, and oxidative stress. Plant-based dietary supplements, particularly Ceylon cinnamon (Cinnamomum ver...

A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain Completed
NCT06074562 Phase: 2 Started: 2023-10-05

The main purpose of this study is to determine the safety and efficacy of LY3556050 versus placebo in participants with diabetic peripheral neuropathic pain (DPNP). The study will lasts approximately 24 weeks, across 3 study periods.

Effect of Melatonin in Patients With Diabetic Peripheral Neuropathy Recruiting
NCT07036796 Phase: 2 Started: 2025-07-04

The aim of the current study is to measure the effect of melatonin as adjunct therapy on oxidative stress, inflammatory markers and clinical outcome in type 2 diabetic patients with diabetic peripheral neuropathy.

Benfotiamine Versus Vitamin B1-6-12 for Diabetic Peripheral Neuropathy Recruiting
NCT07708233 Phase: 4 Started: 2026-07-14

The purpose of this clinical trial is to compare the efficacy of benfotiamine with vitamin B1-6-12 in reducing sensory neuropathy symptoms, numbness and pain in patients with diabetic peripheral neuropathy. The main questions this study aims to answer are: * Does benfotiamine reduce overall sensory ...

A Randomized Controlled Trial on the Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cell Therapy in Subjects With Moderate to Severe Diabetic Peripheral Neuropathy Recruiting
NCT07183761 Phase: 2 Started: 2025-10-01

This clinical trial aims to evaluate the efficacy and safety of human umbilical cord mesenchymal stem cell (hUC-MSC) injection in the treatment of adults with moderate to severe diabetic peripheral neuropathy. Researchers will compare hUC-MSCs injection combined with conventional therapy (experiment...

Thymoquinone as an add-on Therapy for the Management of Patients With Diabetic Peripheral Neuropathy Completed
NCT07313111 Phase: 4 Started: 2024-07-01

The goal of this clinical trial is to evaluate the efficacy of thymoquinone as an adjuvant treatment with pregabalin in the management of diabetic peripheral neuropathy for both sexes older than 18 years. The main questions it aims to answer are: * Whether the use of thymoquinone could improve diabe...

Study to Assess the Efficacy, Safety and Tolerability of MT- 8554 in Subjects With Painful Diabetic Peripheral Neuropathy Completed
NCT03172598 Phase: 2 Started: 2017-07-25

A Study to Investigate the Safety, Tolerability and Efficacy of Multiple Doses of MT-8554 in Subjects with Painful Diabetic Peripheral Neuropathy

Exploratory Study of MT-8554 in Subjects With Painful Diabetic Peripheral Neuropathy Completed
NCT05123196 Phase: 2 Started: 2021-11-16

The purpose of this study is to investigate the efficacy, safety, tolerability and pharmacokinetics of MT-8554, compared to placebo, in subjects with painful diabetic peripheral neuropathy.

A 6-Month Extension Study of VMDN-003-2 to Assess Engensis in Participants With Painful Diabetic Peripheral Neuropathy Completed
NCT04873232 Phase: 3 Started: 2021-05-17

To evaluate the durability of efficacy and long-term safety of intramuscular administration of Engensis or Placebo that was administered in the double-blind, randomized, VMDN-003-2 Placebo-controlled Phase 3 Study.

A Controlled Clinical Trial Assessing the Efficacy of Vitamin B Prophylaxis in Attenuating Paclitaxel-induced Neuropathy and the Imperative Use of Gabapentin in Diabetic Ovarian Cancer Patients and the Potential Effect on Disease Response. Completed
NCT07191587 Phase: N/A Started: 2024-12-01

The goal of this clinical trial is to learn if vitamin B prophylaxis is effective in attenuating chemotherapy-induced peripheral neuropathy in adult ovarian cancer patients. The main questions (primary outcomes) it aims to answer are: * The severity of chemotherapy-induced peripheral neuropathy in o...

Levagen+ Efficacy Study on Diabetic Peripheral Neuropathy Recruiting
NCT07028528 Phase: 2 Started: 2025-07-01

The goal of this clinical trial is to assess the efficacy of Levagen+ supplementation for the symptoms of diabetic peripheral neuropathy (DPN) in patients with DPN. Participants will have remote visits and attend a local pathology centre for blood draws. They will take the study product for 12 weeks...

Evaluation of Efficacy and Safety of VX-548 for Painful Diabetic Peripheral Neuropathy (DPN) Completed
NCT05660538 Phase: 2 Started: 2022-12-20

The purpose of this study is to evaluate the efficacy and safety of VX-548 doses in treating Painful DPN.

Efficacy, Safety, and PK of LX9211 in Participants With Diabetic Peripheral Neuropathic Pain Completed
NCT04455633 Phase: 2 Started: 2020-09-03

Evaluation of the efficacy of a low and high dose of LX9211 compared to placebo in reducing pain related to diabetic peripheral neuropathy (DPNP) over an 11 week assessment period.

Pregabalin and Alpha-lipoic Acid Combination Versus Each Monotherapy in Patients With Diabetic Peripheral Neuropathy Completed
NCT04846673 Phase: 4 Started: 2021-05-14

This study is a randomized, parallel, open-label, multicenter, phase IV clinical trial to assess the efficacy and safety of pregabalin and alpha-lipoic acid combination compared with each monotherapy in patients with diabetic peripheral neuropathy for 12 weeks.

A Study to Learn How Safe BAY2395840 is and How Well it Works in Participants Who Have Diabetic Nerve Pain Completed
NCT05219812 Phase: 2 Started: 2022-02-16

Researchers are looking for a better way to treat people who have diabetic neuropathic pain (DNP), a condition in which diabetes results in pain due to nerve damage. People with diabetes have high blood sugar levels. Over the time, high blood sugar levels can cause damage to the nerves in the body, ...

Agents Found By Disease-Level Search

Searched directly from “Peripheral Neuropathy (Diabetic Peripheral Neuropathy)” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 10-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).

43 agents shown (approved or with trial evidence) — 36 not found by the gene-target search above.

Pregabalin

· 3 trials · source: ClinicalTrials.gov
NCT00370656 NCT01474772 NCT00141219

Duloxetine

· 2 trials · source: ClinicalTrials.gov
NCT00370656 NCT04970121

EverolimusNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01070316

Ischemic Compression (thumb Pressure)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00634738

Lidocaine

· 1 trial · source: ClinicalTrials.gov
NCT06188221

CorticoidsNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06188221

PhosphatidylserineNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02276716

Vitamin B ComplexNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07191587

LenalidamideNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00166452

LenalidomideNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01553149

StimRouter - ControlNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01592344

CTS-6 Evaluation ToolNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07420049

Axon ReflexesNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02549534

Axon FlaresNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02549534

Self-Reported Signs & Symptoms of CIPNNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02549534

AxoGuard® Nerve CapNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03940963

Standard NeurectomyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03940963

Carboplatin

· 1 trial · source: ClinicalTrials.gov
NCT04038502

OlaparibNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04038502

Amitriptyline

· 1 trial · source: ClinicalTrials.gov
NCT00370656

The Prism Adaptation Therapy GroupNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07370012

The Control GroupNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07370012

Pink Pad ® (Xodus Medical Inc., New Kensington, PA)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04343911

acoramidis (AG10)NOT in gene-target list

Approved · 1 trial · source: ClinicalTrials.gov
NCT03536767

Modified Constraint Induced Movement TherapyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03610763

Mexiletine

· 1 trial · source: ClinicalTrials.gov
NCT02561702

Venalafaxine hydrochlorideNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00167856

Ibuprofen ArginineNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04025203

Gabapentin

· 1 trial · source: ClinicalTrials.gov
NCT04025203

SIR2501NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07765446

Group B (Experimental) 1. Maitland's Lumbar Rotation Mobilization 2.Lower Limb Neurodynamic MobilizationNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07050966

Ozone therapyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06799351

Hyperbaric Bupivacaine plus SalineNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07565662

Hyperbaric Bupivacaine plus DexmedetomidineNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07565662

Alpha lipoic acidNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02439879

TNF blockerNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00385086

wrist splintNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06189651

5% dextrose injection using USG-guided nerve hydrodissection methodNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06189651

bone scintigraphyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04849754

Sono-guided injection with ES135NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06328166

Avance Nerve GraftNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07657182

Sural nerve autograftNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07657182

KetamineNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00961194

Generated by the Open Source Medicine Foundation Biomarker Pipeline — 2026-10-08. Data sources: DGIdb, Open Targets, ChEMBL, PubMed, ClinicalTrials.gov. Not medical advice.